Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

4.0K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.0K
Abnormal Proliferation02:23

Abnormal Proliferation

4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

2.2K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.2K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.1K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Pseudogene Oct4-pg5 Upregulates Oct4b Expression To Promote Bladder Cancer Progression By Competing With Mir-145-5p

Pseudogene OCT4-pg5 upregulates OCT4B expression to promote bladder cancer progression by competing with miR-145-5p

Wuer Zhou1, Yue Yang1,2, Wei Wang1,2

  • 1The Department of Urology, General Hospital of Southern Theater Command, PLA, Guangzhou, China.

Cell Cycle (Georgetown, Tex.)
|June 6, 2024

Related Experiment Videos

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells
11:37

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells

Published on: February 18, 2015

13.8K
CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis
10:40

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

2.4K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.5K

View abstract on PubMed

Summary
This summary is machine-generated.

The OCT4-pg5/miR-145-5p/OCT4B network drives bladder cancer (BC) progression and cisplatin resistance by promoting EMT and activating the Wnt/β-catenin pathway. This axis is a potential therapeutic target for BC.

Area of Science:

  • Molecular oncology and cancer genetics focusing on the OCT4-pg5 ceRNA network.
  • Urological pathology investigating the regulatory mechanisms of bladder cancer progression.
  • RNA biology examining the interactions between pseudogenes, microRNAs, and oncogenic signaling pathways.

Background:

Bladder Cancer (BC) represents a significant global health burden as one of the most prevalent malignant neoplasms affecting the urinary system. Prior research has shown that Competing Endogenous RNA (ceRNA) networks function as fundamental regulatory frameworks that influence the clinical prognosis of various human malignancies. These molecular circuits involve pseudogenes and microRNAs that modulate the expression of protein-coding genes through competitive binding sites. Identifying specific biomarkers within these networks remains essential for understanding how tumors transition to advanced pathological grades. Although many regulatory axes have been mapped, the specific role of the OCT4 pseudogene family in urological oncology requires deeper investigation. The biological significance of these non-coding elements often involves their ability to act as decoys for inhibitory microRNAs. This absence of evidence motivated the current exploration into how non-coding transcripts interact with established oncogenic drivers to facilitate tumor growth.

Keywords:
OCT4-pg5OCT4Bbladder cancercompeting endogenous RNA

Frequently Asked Questions

Based on this study's findings, the 3' untranslated region of OCT4-pg5 acts as a competing endogenous RNA that sequesters miR-145-5p. This molecular competition prevents the microRNA from inhibiting OCT4B, leading to its upregulation and the subsequent promotion of tumor cell proliferation and invasion.

The researchers found that OCT4-pg5 promotes the epithelial-mesenchymal transition by activating the Wnt/β-catenin pathway. This activation results in the increased expression of matrix metalloproteinases 2 and 9, as well as the transcription factors ZEB1 and ZEB2, which facilitate cancer progression.

These methods were used to determine how the OCT4-pg5/OCT4B axis alters the cellular response to chemotherapy. The assays revealed that elevated expression of these components reduced cisplatin sensitivity by increasing the proportion of cells in the G1 phase and decreasing the rate of apoptosis.

Related Experiment Videos

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells
11:37

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells

Published on: February 18, 2015

13.8K
CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis
10:40

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

2.4K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.5K

Purpose Of The Study:

This investigation evaluates the functional impact of the OCT4-pg5/miR-145-5p/OCT4B axis on the development and therapeutic resistance of bladder cancer. Researchers sought to determine if OCT4-pg5 expression levels correlate with advanced tumor stages and specific cellular behaviors like invasion. The study examines the competitive mechanism by which the 3' Untranslated Region (3'UTR) of this pseudogene sequesters specific microRNAs to release downstream targets. Another objective involves characterizing the activation of the Wnt/β-catenin signaling pathway in response to pseudogene upregulation. Scientists also aimed to clarify how these genetic interactions alter the sensitivity of malignant cells to standard chemotherapeutic agents like cisplatin. The research team focused on identifying whether the upregulation of specific transcription factors like Zinc Finger E-box Binding Homeobox (ZEB) 1 and 2 occurs as a direct consequence of this axis. The work clarifies whether targeting this specific RNA network could serve as a viable strategy for future clinical interventions.

Main Methods:

The experimental design utilized multiple bladder cancer cell lines to compare transcript levels against those found in normal bladder epithelial cells. Quantitative analysis established the correlation between OCT4-pg5 and OCT4B expression across different pathological tumor grades. Functional assays measured changes in cellular proliferation and invasive capacity following the controlled overexpression of specific RNA components. Molecular competition was verified by examining the binding affinity between the 3' untranslated region (3'UTR) of the pseudogene and miR-145-5p. Protein expression levels for Matrix Metalloproteinases (MMPs) 2 and 9 were quantified to assess the induction of the Epithelial-Mesenchymal Transition (EMT). Flow cytometry and apoptosis assays determined the cell cycle distribution and programmed cell death rates in response to cisplatin treatment. Statistical frameworks were applied to correlate the molecular findings with clinical parameters such as tumor grade and progression risk.

Main Results:

OCT4-pg5 expression was significantly elevated in bladder cancer cell lines compared to healthy controls and showed a strong positive correlation with OCT4B levels. The 3' untranslated region of OCT4-pg5 successfully competed for miR-145-5p, which led to a marked increase in the expression of the OCT4B protein. Overexpression of the pseudogene triggered the epithelial-mesenchymal transition by activating the Wnt/β-catenin pathway and upregulating transcription factors ZEB1 and ZEB2. Increased levels of matrix metalloproteinases 2 and 9 were observed, directly facilitating the enhanced invasion and proliferation of the malignant cells. High expression of the OCT4-pg5/OCT4B axis reduced cisplatin sensitivity by increasing the proportion of cells in the G1 phase and decreasing apoptosis. Conversely, the introduction of miR-145-5p effectively suppressed the aggressive activities and growth patterns of the tested cancer models. These results demonstrate that the pseudogene acts as a potent oncogenic regulator that bypasses normal cellular growth constraints.

Conclusions:

The OCT4-pg5/miR-145-5p/OCT4B axis functions as a primary driver of bladder cancer progression through the modulation of oncogenic signaling. These findings suggest that the pseudogene acts as a molecular sponge that prevents microRNA-mediated suppression of key developmental genes. Activation of the Wnt/β-catenin pathway by this network provides a mechanistic explanation for the observed increase in metastatic potential and epithelial-mesenchymal transition. Clinical management of bladder cancer may eventually incorporate the detection of these RNA transcripts to predict patient response to cisplatin-based chemotherapy. Future research should focus on developing inhibitors that can disrupt the interaction between the pseudogene 3'UTR and its microRNA targets. The study highlights the importance of non-coding RNA networks in determining the aggressive phenotype of urological tumors. This regulatory network represents a promising therapeutic target for patients suffering from advanced or treatment-resistant bladder malignancies.

miR-145-5p

The study's conclusions are specifically confined to bladder cancer progression and the behavior of malignant bladder cell lines. The authors focus on how this axis correlates with advanced tumor grades and the development of resistance to cisplatin treatment within this specific urological malignancy.

The study's authors propose that this specific molecular axis may represent a viable therapeutic target for patients with bladder cancer. They conclude that targeting the OCT4-pg5/miR-145-5p/OCT4B network could potentially overcome cisplatin resistance and inhibit the aggressive progression of the disease.